In this randomized crossover study, the LipoMicel micellar formulation produced significantly higher baseline-adjusted systemic glutathione exposure than standard glutathione despite a lower administered dose, the researchers explained
Certificate of Analysis Certificates of Analysis Janoshik Third-party tested Independent analytical lab Latest safety testing Sterility TAMC/TYMC Jul 2026 Heavy metals As/Cd/Pb not detected Feb 2026 Endotoxin 8.159 EU/vial Feb 2026 Endotoxin, sterility, and heavy-metals reports are run on individual lots on a rotating basis, separate from the identity/purity assay above not on every lot
This multi-receptor activation enables: GLP-1R activation enhances glucose-dependent insulin secretion and reduces appetite through hypothalamic signaling GIPR activation (highest potency: EC50 0.0643 nM) promotes insulin secretion and modulates lipid metabolism GCGR activation (EC50 5.79 nM) increases energy expenditure and promotes hepatic fat oxidation Combined receptor engagement produces dose-dependent reductions in body weight and improvements in glycemic control Research demonstrates that GLP3s balanced activation across three receptors produces superior metabolic effects compared to single or dual agonists, with phase 2 trials showing up to 24.2% weight reduction in 48 weeks[2]
They argue that the appropriate response is not a blanket ban but a structured framework: quality-controlled compounding, mandatory prescriber oversight, and data collection that builds the evidence base over time
